A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
Completed · Phase 1
Conditions studied: COVID-19, SARS-CoV-2 Infection
In brief
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Key facts
- Study ID
- NCT06147063
- Run by
- AstraZeneca
- People needed
- 243
- Starts
- 2023-11-27
- Expected to finish
- 2025-03-27
- Last updated by the study team
- 2025-06-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Long Beach, California, United States
- Research Site — Rolling Hills Estates, California, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Wichita, Kansas, United States
- Research Site — North Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.